Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020088164 - BISPECIFIC ANTIBODY AND USE THEREOF

Publication Number WO/2020/088164
Publication Date 07.05.2020
International Application No. PCT/CN2019/108057
International Filing Date 26.09.2019
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61P 37/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
A61P 35/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12N 15/62 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Applicants
  • 山东新时代药业有限公司 SHANDONG NEWTIME PHARMACEUTICAL CO., LTD [CN]/[CN]
Inventors
  • 李强 LI, Qiang
  • 贾世香 JIA, Shixiang
  • 赵丽丽 ZHAO, Lili
  • 张贵民 ZHANG, Guimin
  • 马心鲁 MA, Xinlu
  • 严源 YAN, Yuan
  • 李振宇 LI, Zhenyu
  • 胡兴霞 HU, Xingxia
  • 张玉华 ZHANG, Yuhua
  • 李斌 LI, Bin
Priority Data
201811294887.401.11.2018CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) BISPECIFIC ANTIBODY AND USE THEREOF
(FR) ANTICORPS BISPÉCIFIQUE ET SON UTILISATION
(ZH) 双特异性抗体及其用途
Abstract
(EN)
A bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests. The method for constructing a bispecific antibody is simple, and avoids the possibility of mismatching between two sets of light chains and heavy chains of a heterologous bispecific antibody, thus the difficulty of antibody purification is reduced, the affinity of the obtained antibody is high, the side effects of induced cytokines are few, and safety is high.
(FR)
La présente invention concerne un anticorps bispécifique, qui se lie de manière spécifique à l'antigène de surface CD3 de cellules immunitaires et à l'antigène BCMA sur la surface de cellules tumorales et qui peut se lier à CD3 humain avec une affinité élevée, induisant une prolifération de lymphocytes T, et induisant des effets de destruction de cellules tumorales. L'anticorps bispécifique peut être utilisé pour induire la mort spécifique aux lymphocytes T de cellules cibles dans des tests in vitro. Le procédé de préparation d'un anticorps bispécifique est simple, et évite la possibilité d'une désadaptation entre deux ensembles de chaînes légères et de chaînes lourdes d'un anticorps bispécifique hétérologue, ainsi, la difficulté de purification d'anticorps est réduite, l'affinité de l'anticorps obtenu est élevée, les effets secondaires des cytokines induites sont faibles, et la sécurité est élevée.
(ZH)
一种双特异性抗体,特异性结合免疫细胞的表面抗原CD3和肿瘤细胞表面的BCMA抗原,其能够以高亲和力与人CD3结合并诱导T细胞增殖,介导肿瘤细胞杀伤作用。所述双特异性抗体在体外测试可用于介导T细胞特异杀伤靶细胞。该双特异性抗体构建方法简单,避免了异源双特异性抗体两组轻链与重链错配的可能性,从而降低了抗体纯化的难度,得到的抗体亲和力高,引起的细胞因子副作用小,安全性高。
Latest bibliographic data on file with the International Bureau